Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psoriatic Immune Response to Tildrakizumab
NCT05390515Phase 4Recruiting
- Sponsor
- University of California, San Francisco
- Start
- Sep 2022
- Primary completion
- Sep 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tildrakizumab in Psoriasis vulgaris (PV), sponsored by University of California, San Francisco. Primary endpoint: Psoriasis Area and Severity Index at 3 months. Started Sep 2022; status: recruiting.
02
Drugs
tildrakizumab
03
Conditions
Psoriasis vulgaris (PV)
Beyond the preview
Go deeper on NCT05390515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05390515.